This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.


quadrivalent influenza vaccine (recombinant, prepared in cell culture)

This is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.


Flu just met its genetic match

Supemtek® Quadrivalent Influenza Vaccine (recombinant, prepared in cell culture) is the first recombinant influenza vaccine in Europe, indicated for active immunisation for the prevention of influenza disease in adults.1

Supemtek is manufactured to offer an exact genetic match to the WHO-predicted viral strain haemagglutinin (HA) antigen.1,2


Supemtek efficacy

Supemtek has shown 30% greater relative efficacy (1% absolute efficacy) against influenza-like illness versus standard-dose egg-based quadrivalent influenza vaccine (QIVe) (2.2% vs 3.2% influenza attack rate) in adults ≥50 years of age (Figure 1).1,2

A randomised, controlled trial of 8,604 adults ≥50 years of age during the 2014/15 influenza season found that Supemtek showed 30% greater relative efficacy (1% absolute efficacy; 2.2% vs 3.2% influenza attack rate) against influenza-like illness (reverse-transcriptase polymerase chain-reaction [RT-PCR] confirmed) versus standard-dose QIVe (95% confidence interval [CI]: 10, 47).1,2

RT-PCR-confirmed influenza-like illness (primary endpoint) attack rates were 3.2% (138 infections/4301) modified per-protocol population and 2.2% (96 infections/4303) modified per-protocol population with standard-dose QIVe and Supemtek, respectively.1,2

Additionally, when considering the secondary endpoint, culture-positive influenza-like illness, Supemtek showed 43% greater relative protection (1% absolute reduction) compared with standard-dose QIVe. Culture-positive influenza-like illness attack rates were 2.3% (101 infections) and 1.3% (58 infections) for standard-dose QIVe and Supemtek, respectively.1,2

Supemtek Immunogenicity

Supemtek showed comparable immunogenicity to standard-dose QIVe in adults aged 18–49 years of age.1,4

Comparison of immunogenicity with Supemtek or QIVe during the 2014/15 influenza season was tested according to co-primary endpoints, geometric mean antibody titres (GMT) (Table 1) and seroconversion rates (SCR) (Table 2) at Day 28, across influenza strains in a randomised, controlled trial of 1,350 adults.1,2

Supemtek responses to three of the four influenza strains (A/H1N1, A/H3N2 and B/Yamagata) met non-inferiority criteria. Supemtek responses to B/Victoria/60/2008 did not meet non-inferiority criteria; however, responses were low in both groups so comparisons could not be drawn.1,4


Recombinant technology

Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.2,3

Increased HA content

Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell and egg-based standard-dose quadrivalent influenza vaccines.2

Adverse Events

Supemtek safety profile

In two separate studies of adults ≥50 years of age and 18–49 years, Supemtek showed a comparable safety profile to standard-dose QIVe (Figures 3 and 4).2,4

The most commonly reported reactions after vaccine administration were injection-site reactions (tenderness and pain). Severity of reactions were mild to moderate. Onset usually occurred within the first 3 days after vaccination. All reactions resolved without sequelae.1

Figure 3 goes here...

Figure 4 goes here...

Ways to order

You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre. Read more about ordering vaccines.

CALL 0800 854 430

  1. Supemtek Summary of Product Characteristics. (Accessed October 2023).
  2. Dunkle LM, et alN Engl J Med. 2017;376:2427–36.
  3. Centers for Disease Control and Prevention. How influenza (flu) vaccines are made. (Accessed October 2023).
  4. Dunkle LM, et alJ Infect Dis. 2017;216:1219–26.

MAT-XU-2301126 (v2.0) Date of preparation: December 2023